PRA Health Sciences, Inc.: management transactions · United States · SEC (Form 4)

About PRA Health Sciences, Inc.

PRA Health Sciences, Inc. (historical ticker: PRAH) was a U.S.-based clinical research services company and, before its acquisition, was listed on NASDAQ in the United States. For French-, Belgian- and Swiss-based investors, PRA should be understood as a contract research organization (CRO): a specialist outsourced provider that supports pharmaceutical companies, biotechnology firms and medical device makers across the clinical development process. The company was founded in 1976 and was headquartered in Raleigh, North Carolina, a major U.S. life-sciences hub. ([forbes.com](https://www.forbes.com/companies/pra-health-sciences/?utm_source=openai)) Operationally, PRA offered full-service outsourced clinical development capabilities spanning trial planning, site management, data management, biostatistics, clinical monitoring, pharmacovigilance and regulatory support. Its business model was built around serving sponsors that need help designing and executing complex clinical programs, often across multiple therapeutic areas and geographies. In the CRO industry, competitive strength typically depends on scale, therapeutic expertise, execution quality, global reach and long-standing sponsor relationships, and PRA positioned itself as a global partner rather than a niche local provider. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/p/NASDAQ_PRAH_2016.pdf?utm_source=openai)) Geographically, the company maintained an international footprint to support multinational studies and to meet the regulatory and operational requirements of global drug development. That breadth mattered because clinical trials are increasingly cross-border and highly regulated, making local infrastructure and global coordination critical. A defining corporate event came in 2021: ICON plc announced and then completed its acquisition of PRA Health Sciences in an approximately $12 billion cash-and-stock transaction. Following completion, PRA ceased trading as a standalone public company and was integrated into ICON. ICON described the transaction as creating a world-leading healthcare intelligence and clinical research organization. ([iconplc.gcs-web.com](https://iconplc.gcs-web.com/news-releases/news-release-details/icon-acquire-pra-health-sciences-creating-world-leader?utm_source=openai)) From an equity-analysis standpoint, the key takeaway is that PRAH is now primarily a legacy reference rather than an active standalone listed issuer. The company’s historical profile is still useful for sector comparison and for understanding the evolution of the CRO industry, but its business, clients and capabilities were absorbed into ICON as of July 1, 2021. Recent material developments are therefore centered on the acquisition and integration rather than on independent standalone reporting. For current investors, that means PRAH should be treated as a historical U.S. NASDAQ healthcare-services name, not as an ongoing independent equity story. ([iconplc.gcs-web.com](https://iconplc.gcs-web.com/news-releases/news-release-details/icon-acquisition-creates-world-leading-healthcare-intelligence/?utm_source=openai))